Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Tekla Life Sciences Investors

Tekla Life Sciences Investors (HQL) Stock Overview

Explore Tekla Life Sciences Investors’s financial performance, market position, analyst ratings, and future outlook.

HQL●NYSE
Financial ServicesAsset Management
$21.55
$0.83(3.71%)
U.S. Market opens in 9h 39m

Tekla Life Sciences Investors (HQL)

Meyka AI Score

Z

Key Financials

Market Cap656.2M
P/E Ratio3.19
EPS (TTM)$-0.42
ROE0.37%
Fundamental Analysis

AI Price Forecasts

1 Month$22.90
3 Months$23.68
1 Year Target$22.24

HQL Stock Analysis & Investment Overview (NYSE)

Our AI-powered analysis of Tekla Life Sciences Investors (NYSE: HQL) gives investors deep insight into how the stock performs on the NYSE exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Tekla Life Sciences Investors's NYSE-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of HQL on the NYSE shows an RSI of 59.67, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $22.24 for the NYSE listing.

Key metrics behind Tekla Life Sciences Investors's NYSE-traded stock include a P/E ratio of 3.19 and a market capitalization of 656.2M. Combined with our AI analysis, these give both institutional and retail investors a clear view of HQL on the NYSE.

Price Performance (NYSE: HQL)

1-Day Change
-3.57%
5-Day Change
-1.60%
1-Month Change
12.10%
3-Month Change
25.54%
6-Month Change
28.30%
Year-to-Date (YTD) Change
28.61%
1-Year Change
58.33%
3-Year Change
66.26%
5-Year Change
-4.26%
All-Time (Max) Change
43.87%

Contact Information

https://www.aberdeeninvestments.com/en-us/investor/funds/view-all-funds/abrdn-life-sciences-investors/common-stock/us87911k1007
617 772 8500
100 Federal Street, Philadelphia, PA, 19103

Company Facts

IPO DateMay 1, 1992
CountryUS
Actively Trading

Frequently Asked Questions